Kayexalate Calcium (Calcium Polystyrene Sulfonate)

Calcium Polystyrene Sulfonate is a cation exchange resin that stays within the gut. Its sulfonate groups exchange calcium ions for potassium ions, trapping potassium in the resin. The bound potassium is then eliminated in the feces, reducing the amount of potassium absorbed into the bloodstream.

The dosage of Kayexalate Calcium is individualized by the prescribing clinician based on the severity of hyperkalemia, renal function, and other patient‑specific factors. The prescriber determines the appropriate amount, frequency, and route of administration.

Safety data for Kayexalate Calcium in pregnancy and lactation are limited, and the product’s pregnancy category is unknown. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kayexalate Calcium uses calcium as the exchange ion, whereas sodium polystyrene sulfonate exchanges sodium for potassium. Calcium exchange may be preferred in patients where sodium load is a concern, but both agents share similar efficacy in lowering serum potassium and have comparable safety profiles.

Store Kayexalate Calcium at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to extreme heat or direct sunlight to maintain its stability and effectiveness.

Kayexalate Calcium can be given orally as a suspension mixed with water or juice, or administered rectally as an enema. The exact method, volume, and frequency are determined by the prescriber according to the patient’s clinical condition.

The most serious risks include intestinal necrosis, severe electrolyte disturbances such as hypokalemia or hypocalcemia, and bowel obstruction. Patients should be monitored closely for abdominal pain, signs of bleeding, or abrupt changes in electrolyte levels.

Kayexalate Calcium should be avoided in patients with known hypersensitivity to calcium polystyrene sulfonate, severe hypercalcemia, active bowel obstruction, or those who cannot tolerate oral or rectal administration. Clinicians should also exercise caution in individuals with compromised gastrointestinal integrity.